"More than 5 million Americans are living with Alzheimer's disease, a 10 percent increase since the last Alzheimer's Association estimate five years ago on track for skyrocketing Alzheimer's once the baby boomers start turning 65 in 2011."
- ASSOCIATED PRESS, MARCH 20, 2007

The direct and indirect cost of AD to society is in the range of $100 billion annually. Present AD therapies moderately slow the progression of the disease, without reversing the deficit or improving cognition.

Neuronascent aims to develop a new class of neurogenic therapeutics that reverse the cognitive deficit in AD patients by stimulating and protecting new neuron growth. Neuronascent's chemically-diverse, orally-active neurogenic compounds will be developed into therapeutics that promote the formation of new neurons and replace damaged neurons in key areas of the brain. Laboratory tests indicate that these compounds promote new brain cells that will survive under neurodegenerative conditions. Our AD program is in the preclinical phase of development.

For more information on Alzheimer's disease, please visit the Alzheimer's Association at www.alz.org.